“We are pleased to announce the completion of clinical supply manufacturing for Bria-PROS+, our next generation personalized immunotherapy candidate for prostate cancer,” said William Williams, president and CEO.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell adds Penn Medicine as Phase 3 breast cancer study site
- BriaCell receives FDA clearance to initiate Bria-BRES+ trial
- BriaCell presents anti-cancer activity of Bria-OTS
- BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR
- BriaCell Therapeutics Reports Rising Losses and Funding Pressure